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CD8 T Cell Tolerance to a Tumor-Associated Self-Antigen Is
Reversed by CD4 T Cells Engineered To Express the Same
T Cell Receptor
Sara Ghorashian,*,†,1 Pedro Velic¸a,*,†,1 Ignatius Chua,* Anne-Marie McNicol,*
Ben Carpenter,† Angelika Holler,* Emma Nicholson,* Maryam Ahmadi,*
Mathias Zech,* Shao-An Xue,* Wolfgang Uckert,‡ Emma Morris,* Ronjon Chakraverty,†,2
and Hans J. Stauss*,2
Ag receptors used for cancer immunotherapy are often directed against tumor-associated Ags also expressed in normal tissues.
Targeting of such Ags can result in unwanted autoimmune attack of normal tissues or induction of tolerance in therapeutic
T cells. We used a murine model to study the phenotype and function of T cells redirected against the murine double minute protein
2 (MDM2), a tumor-associated Ag that shows low expression in many normal tissues. Transfer of MDM2-TCR–engineered T cells
into bone marrow chimeric mice revealed that Ag recognition in hematopoietic tissues maintained T cell function, whereas
presentation of MDM2 in nonhematopoietic tissues caused reduced effector function. TCR-engineered CD8+ T cells underwent
rapid turnover, downmodulated CD8 expression, and lost cytotoxic function. We found that MDM2-TCR–engineered CD4+ T cells
provided help and restored cytotoxic function of CD8+ T cells bearing the same TCR. Although the introduction of the CD8
coreceptor enhanced the ability of CD4+ T cells to recognize MDM2 in vitro, the improved self-antigen recognition abolished their
ability to provide helper function in vivo. The data indicate that the same class I–restricted TCR responsible for Ag recognition
and tolerance induction in CD8+ T cells can, in the absence of the CD8 coreceptor, elicit CD4 T cell help and partially reverse
tolerance. Thus MHC class I–restricted CD4+ T cells may enhance the efficacy of therapeutic TCR-engineered CD8+ T cells and
can be readily generated with the same TCR. The Journal of Immunology, 2015, 194: 000–000.
A
doptive transfer of T cells genetically engineered to
express TCRs for tumor-associated Ags (TAAs) is ac-
tively being explored as therapy for cancer (1–4). Can-
didate Ags are assessed by criteria such as their immunogenicity,
expression levels within neoplastic compared with normal cells,
and whether they have shared expression in patients with different
tumor types (5). Targeting TAAs derived from proteins with a di-
rect role in neoplastic transformation is attractive because this
may prevent development of Ag-loss variants that escape T cell
attack. Unfortunately, many of these proteins are also expressed in
normal tissues. Targeting of such Ags for therapeutic purposes
may cause detrimental autoimmune damage, or it may induce
unresponsiveness of adoptively transferred T cells due to chronic
Ag exposure. In this study we analyzed to what extent the ex-
pression of TAAs in normal tissues impairs T cell function in vivo,
and whether it is possible to develop strategies to reverse this.
The murine double minute protein 2 (MDM2) oncogene is
required for cellular transformation through its function in in-
activating the p53 tumor suppressor protein (6, 7). Although
overexpressed in many cancers, it is also found in normal tissues,
albeit at lower levels (6–8). As a consequence, high-avidity
MDM2-specific T cells are deleted from the repertoire in the
thymus or become subject to peripheral tolerance mechanisms
(9). To bypass self-tolerance, we previously used an allorestricted
strategy to generate high-avidity allo-MHC–restricted CTLs spe-
cific for peptide epitopes of MDM2 in both human (9) and mu-
rine (10) T cell repertoires. A murine MDM2-derived peptide,
pMDM100, that is naturally presented on H2-Kb MHC class I
(MHC-I) molecules, is recognized by high-avidity allorestricted
MDM2-specific CTL clones from H2d BALB/c mice (10). We
have previously demonstrated that whereas naturally presented Kb/
pMDM100 peptide in normal hematopoietic cells is insufficient
to induce killing, endogenous presentation of Kb/pMDM100 in
several tumor lines readily triggers Ag-specific cytotoxicity (10,
11). However, although the CTL clones can induce potent anti-
tumor effects in vivo, they become rapidly exhausted under con-
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ditions where Ag is also expressed in normal tissues (11). In
a therapeutic setting, this loss of function may reduce antitumor
efficacy.
Provision of CD4+ T cell help (Th) during primary or recall
responses, or during chronic exposure to Ag, has been demon-
strated to enhance CD8+ T cell–mediated immunity (12, 13). Th
responses augment CTL functions directly through release of ef-
fector cytokines or indirectly through licensing of dendritic cells
(DCs) (13). However, application of this approach in the clinic has
been limited by the paucity of validated MHC class II (MHC-II)–
restricted TAAs and/or the lack of expression of MHC-II in cancer
cells (14). One potential means of overcoming these barriers is
the redirection of CD4+ T cell specificity through gene transfer
of MHC-I–restricted TCRs that recognize TAAs (15–17). CD4+
T cells engineered in this way can proliferate and release Th
cytokines in response to MHC-I peptide ligand (15–17). We have
shown previously that CD4+ T cells modified to express an
influenza-specific MHC-I–restricted TCR can provide help in vivo
to CD8+ T cells expressing the identical TCR (17). However, in
this model Ag system, the CD8+ T cell population was not af-
fected by exposure to naturally expressed TAA in normal tissues.
We therefore sought to determine how chronic Ag exposure
affects the functional profile of CD4+ and CD8+ T cells expressing
the same TAA-specific TCR, and whether such CD4+ T cells can
help to overcome Ag-related dysfunction in CD8+ T cell pop-
ulations.
In this study, we find that transfer of a high-avidity, MDM2-
specific TCR into CD8+ T cells leads to a rapid loss of their fit-
ness as a consequence of Ag recognition upon self. T cell ex-
haustion in Ag-expressing hosts can be partially reversed by
cotransfer of CD4+ T cells engineered to express the identical
TCR, where the absence of the CD8 coreceptor enables preser-
vation of helper function.
Materials and Methods
Mice and cell lines
C57BL/6 (B6), B6.PL (Thy1.1), B6.SJL (CD45.1), BALB/c, B63 BALB/c
F1 (CB6F1), B6 Rag1
2/2 (B6.129S7-Rag1tm1Mom/J), BALB/c Thy1.1
(By.PL(B6)-Thy1a/ScrJ), and Rag22/2 OT-II mice were purchased from
Harlan Laboratories (Loughborough, U.K.), Charles River Laboratories
(Wilmington, MA), or The Jackson Laboratory (Bar Harbor, ME) and
maintained in the University College London animal facility. Experiments
were performed in accordance with Home Office (Animals Scientific Pro-
cedures Act 1986) and local ethics committee guidance. RMA-S cells (H2b)
are a T cell lymphoma cell line and are TAP-deficient (18). Ecotropic
Phoenix packaging cells (PEco) used for retroviral particle production
were a gift from Dr. G.P. Nolan (Stanford University, Stanford, CA).
Peptides
The peptide pMDM100 (YAMIYRNL) binds to H2-Kb MHC-I (19) and the
peptide pNP366 (ASNENDAM) of influenza virus A nucleoprotein (NP)
binds to H2-Db MHC-I (20). The peptide pOVA323 (ISQAVHAAHAEI-
NEAGR) of chicken egg OVA binds to I-Ab and is recognized by the OT-II
TCR. All peptides were generated by ProImmune (Oxford, U.K.).
Retroviral constructs
Tcra and Tcrb genes were cloned as described previously from the influ-
enza A NP–specific F5 CTL clone recognizing pNP366 (21) as well as
from the pMDM100-specific CTL clones 3f3b (high avidity) and 6a5d
(low avidity) (22). Tcra and Tcrb genes were codon optimized and two
c-myc tag sequences inserted downstream of the Tcra leader sequence
(23). Additional disulfide cysteine bonds were engineered between the
TCRa and TCRb constant regions and each gene was separated by a 2A
sequence before cloning into the pMP71 retroviral vector, a gift from
Dr. C. Baum (Medical School Hannover, Hannover, Germany). For experi-
ments requiring cotransduction with CD8ab, CD8a and CD8b genes
separated by a 2A sequence were cloned into pMP71. Murine T cells were
transduced as described previously (22).
Adoptive transfer of transduced lymphocytes
Purified CD8+ and CD4+ T cells were transduced with each retroviral
construct. Three days later, cells were analyzed by FACS for TCR ex-
pression and either injected as bulk populations or sorted on a BD FACS-
Aria flow cytometer to generate pure CD8+ TCR-expressing (c-myc+ or
Vb11+) populations before transfer. Recipient mice were irradiated (5.5
Gy) 4 h before i.v. injection of 0.1–1 3 106 TCR-transduced cells. Cell
numbers were corrected for TCR expression in each experiment. Bone
marrow–derived DCs were generated as described (24). In some experi-
ments, 100 mg anti-CD8–depleting Ab (2.43, Bio X Cell, West Lebanon,
NH) was administered i.p. at weekly intervals.
Bone marrow transplantation
Hematopoietic chimeric animals were generated as described previously
(25). Recipient mice were lethally irradiated (B6, 11 Gy; CB6F1, 10 Gy;
BALB/c, 8 Gy) and reconstituted with 5 3 106 recipient-type or 15 3 106
allogeneic T cell–depleted bone marrow cells. In some experiments,
BALB/c (Kb-negative) T cells were transduced and adoptively transferred
to recipient chimeras. For this, it was necessary to derive BALB/c origin
T cells that would not mount alloresponses to Kb. Thus, CB6F1 mice were
lethally irradiated and reconstituted with 10 3 106 T cell–depleted BALB/c
bone marrow cells and 10 3 106 unselected bone marrow cells from B6
Rag12/2 mice. Chimeric animals were allowed to reconstitute stable he-
matopoiesis for a minimum of 12 wk before being used either as spleno-
cyte donors or recipients for adoptive transfer. Where BALB/c origin
T cells were derived from chimeric animals, Kb-expressing splenocytes
were depleted by magnetic bead separation after preincubating with anti–
H2-Kb Ab (AF6-88.5, BD Pharmingen). Transduction of these splenocytes
was then carried out as already described.
Flow cytometry
The following mAbs and isotype controls were obtained from eBioscience
(Hatfield, U.K.): anti-CD8b (H35-17.2), anti-CD4 (GK1.5), anti-Thy1.1
(HIS51), anti-CD45.1 (A20), anti-CD45.2 (104), and anti-Vb11 (RR3-
15). We obtained the following mAbs and isotype controls from BD
Pharmingen: anti-CD44 (IM7), anti-CD62L (MEL-14), anti–programmed
death 1 (PD-1; J43), and anti-CD69 (H1.2F3). A murine anti–c-myc
(9E10, Santa Cruz Biotechnology) and a secondary rat anti-murine IgG
Ab (X56, BD Pharmingen) were used to assess TCR a-chain expression.
Samples were run on a BD LSRFortessa (BD Biosciences, Oxford, U.K.)
and analysis was performed using FlowJo software (Tree Star).
Transduced T cell populations were identified based on a live lymphocyte
gate, followed by expression of a congenic marker (where relevant), ex-
pression of a coreceptor or coreceptors (CD4 and/or CD8), and then by
expression of the c-myc tag (for MDM2- or LoMDM2-TCR–transduced
populations) or by expression of Vb11 (F5-TCR–transduced populations).
Where intensity of CD8 expression was investigated, this was excluded
from the initial gating strategy, and transduced populations were identified
from expression of the relevant congenic marker as well as the introduced
TCR.
Ag-specific cytokine production
ELISA was used to measure IFN-g and IL-2 concentrations, as described
previously (17).
51Cr-release and in vivo cytotoxicity assays
Cytotoxic activity was determined using a 4-h 51Cr-release assay. In vivo
cytotoxicity was performed as described previously (22, 26). In brief,
B cells were isolated from syngeneic splenocytes, divided into equal ali-
quots, and loaded with either the pMDM100 or pNP366 peptides. The NP
peptide–loaded B cells were stained with 0.5 mM and the MDM2 peptide–
loaded B cells were loaded with 5 mM CFSE. The B cell aliquots were
mixed at a 1:1 ratio. Total B cells (1 3 107) were then injected i.v. into
recipient mice after prior adoptive transfer of TCR-transduced T cells. The
relative killing of these differentially labeled B cells was then determined
by flow cytometry of splenocyte preparations after 16 h, and the specific
lysis of B cell targets was calculated as described previously (22, 26).
Histological analysis
Histological sections of skin, liver, lung, and colon from recipients of
adoptively transferred T cells were stained with H&E and were assessed for
evidence of immunopathology in a single blinded fashion. Images of
representative sections were taken on an Olympus IX70 microscope fitted
with a Canon EOS 1000D camera, using either a 310 (skin, liver, lung) or
320 (colon) objective lens.
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Statistical analysis
Statistical comparisons involved the Mann–Whitney two-tailed test. A
p value ,0.05 was considered significant.
Results
CD8+ T cells transduced with high-avidity MDM2-TCR
demonstrate reduced fitness in vitro
In initial experiments, we transduced purified CD8+ T cells from
B6 splenocytes with retrovirus encoding codon-optimized TCRa
and TCRb genes derived from T clones recognizing an identi-
cal Kb-restricted epitope of MDM2 (Kb/pMDM100) with high
(MDM2-TCR) or low avidity (LoMDM2-TCR). To avoid pre-
existing tolerance, the Kb-restricted CD8+ T cell clones were
originally isolated from BALB/c splenocytes by in vitro stimula-
tion with Kb-positive stimulator cells coated with pMDM100
peptides (10). High-avidity T cell clones recognized lower peptide
concentrations and killed MDM2-expressing tumors more effec-
tively than did low-avidity clones (10). The TCR genes were
isolated and modified to contain additional disulfide cysteine
bonds between the constant a and b regions to improve TCR
expression and to reduce mispairing with endogenous TCR chains
(27) (Fig. 1A). c-myc tags were inserted at the N-terminal end of
the TCR a-chains (Fig. 1A) (23). Use of c-myc–specific Abs
allowed a comparison of TCR expression (Fig. 1B), whereas
owing to predicted affinity differences, this comparison was not
possible using Kb/pMDM100 multimer reagents. Following
transduction and in vitro expansion, T cells expressing the MDM2
or the LoMDM2-TCR both killed RMA-S target cells pulsed with
relevant peptide (Fig. 1C). In contrast, the levels of naturally
processed pMDM100 peptide in the tumor cell lines MBL-2 and
C205 were sufficient to induce Ag-specific cytotoxicity by T cells
expressing MDM2-TCR but not LoMDM2-TCR, consistent with
the activity of the parental clones (11) (Supplemental Fig. 1).
Although TCR-transduced CD8+ T cells recapitulated the cyto-
toxic function of the parental clones, this was not observed when
effector cytokine production was tested (Fig. 1D). Whereas T cells
expressing LoMDM2-TCR produced IFN-g following stimulation
overnight with RMA-S targets pulsed with relevant peptide, no
cytokine production above background was observed when T cells
expressing the MDM2-TCR were stimulated in the same way.
We hypothesized that the defective cytokine production of Kb-
positive B6 T cells was due to tolerance arising from cognate self-
antigen recognition in vitro. Indeed, as an inhibitor of the cell
cycle regulator p53, MDM2 protein expression in T cells is in-
creased significantly during activation (28). To test this possibility,
we transduced CD8+ T cells from B6 or BALB/c mice with the
FIGURE 1. MDM2-TCR–transduced T cells demonstrate cytotoxicity but impaired cytokine generation. (A) Map of TCR gene sequences inserted into
pMP71 retroviral vector. (B) Expression of c-myc tag used to track introduced TCR sequences in CD8+ T cells. Isotype controls are represented by gray-
filled histograms. Data are representative of .20 independent experiments. (C) MDM2-TCR–transduced (squares) and LoMDM2-TCR transduced (circles)
T cells were restimulated once before being incubated with 51Cr-labeled, peptide-loaded targets (filled symbols, relevant peptide; open symbols, control
peptide) in a standard cytotoxicity assay. Data are representative of three independent experiments. Error bars represent SEM of triplicate values. (D)
MDM2-TCR–transduced CD8+ T cells and LoMDM2-TCR–transduced CD8+ T cells were stimulated overnight with peptide-loaded targets on day 5
following transduction. IFN-g concentrations within the culture supernatants were then evaluated by ELISA. Results are pooled from seven independent
experiments. Error bars represent SD. (E) IFN-g generation by BALB/c and B6 MDM2-TCR–transduced CD8+ T cells following overnight stimulation with
peptide-loaded targets. Data are representative of two independent experiments. All statistically significant comparisons are depicted with the relevant
p value; all other comparisons are not significantly different.
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MDM2-TCR and tested their IFN-g production in response to
relevant peptide. BALB/c cells, lacking Kb, are incapable of
presenting pMDM100 to the MDM2-TCR. As shown in Fig. 1E,
BALB/c but not B6 CD8+ T cells transduced with MDM2-TCR
were able to produce IFN-g after stimulation with relevant pep-
tide.
Supporting the notion that self-antigen recognition impaired
function of MDM2-TCR–expressing CD8+ T cells, transduced
cells had an activated phenotype even in the absence of target cells
exogenously loaded with peptide. Thus, the forward scatter size of
B6 CD8+ T cells expressing the MDM2-TCR was larger than that
of B6 T cells expressing the LoMDM2-TCR or BALB/c T cells
expressing the MDM2-TCR (Fig. 2A). Furthermore, within B6
T cells, expression of high-avidity MDM2-TCR was associated
with elevated expression of the activation markers CD69, CD44,
and PD-1 and with reduced expression of CD62L, whereas this
was not the case in BALB/c T cells (Fig. 2B). Additional analysis
of transduced B6 T cells showed that in the same cultures only the
T cell subset expressing the MDM2-TCR displayed upregula-
tion of PD-1, whereas the PD-1 expression level in gated
MDM2-TCR2 B6 T cells was similar to that of BALB/c T cells
(Supplemental Fig. 1). In addition to PD-1, B6 T cells expressing
the MDM2-TCR expressed elevated levels of the inhibitory
receptors LAG-3, 2B4, and NKG2A when compared with T cells
expressing the F5-TCR (Supplemental Fig. 1). Finally, staining for
annexin V and propidium iodide revealed an increased level of
activation-induced apotosis when the MDM2-TCR was expressed
in B6 T cells but not when it was expressed in BALB/c T cells
(Supplemental Fig. 2).
Taken together, the in vitro data indicated that MDM2-TCR–
transduced B6 T cells were able to display Ag-specific cytotox-
icity. The data also indicated that, in the absence of exogenous
peptide, stimulator cells capable of presenting endogenous MDM2
induced activation and apoptosis of freshly transduced T cells
expressing the MDM2-TCR. This activated phenotype was asso-
ciated with increased levels of LAG-3, 2B4, and NKG2A and
impaired cytokine production when the T cells were further
stimulated with peptide-pulsed stimulator cells.
MDM2-TCR–transduced CD8 T cells lose cytotoxic functions
upon transfer to Ag-expressing hosts
To determine the in vivo fate of CD8+ T cells expressing the
MDM2-TCR, we adoptively transferred B6 T cells (CD45.1) to
sublethally irradiated B6 CD45.2 hosts. As a control, we used
CD8+ T cells expressing the F5-TCR (Vb11+) specific for an
influenza-derived epitope, as these were not affected by recogni-
tion of self-antigen. Peripheral blood taken at day 15 following
transfer showed that the relative frequency of MDM2-TCR–
expressing CD8+ T cells was higher than F5-TCR–expressing
T cells, although by day 22, the percentage was similar in the two
groups of mice (Fig. 3A). At day 29, the absolute numbers of
MDM2- and F5-TCR–transduced T cells were similar in spleen
and bone marrow, whereas lymph nodes showed a greater number
of F5-TCR–transduced T cells (Fig. 3B). To evaluate in vivo
turnover of TCR-transduced CD8+ populations, mice received
BrdU in their drinking water between days 24 and 29. As shown
in Fig. 3C, CD8+ T cells expressing the MDM2-TCR showed
greater BrdU incorporation compared with T cells expressing the
FIGURE 2. Ag recognition upon self by MDM2-TCR–transduced CD8+ T cells induces an activated PD-1high phenotype. Splenocytes of B6 or BALB/c
origin were transduced with the MDM2-TCR and LoMDM2-TCR. TCR-transduced T cells were then analyzed by flow cytometry. (A) Representative
forward scatter (FSC) histogram of MDM2-TCR–transduced (red line) and LoMDM2-TCR–transduced (blue line) CD8+ T cells of B6 (left plot) and
BALB/c (right plot) origin at 72 h after transduction. Graph shows ratio of median FSC of MDM2- to LoMDM2-transduced CD8+ T cells of B6 (d) or
BALB/c (n) origin. Each pair of datum points represents an independent experiment. (B) Flow cytometric histograms of surface expression of CD44,
CD62L, CD69, and PD-1 of MDM2-TCR–transduced (red lines) or LoMDM2-TCR–transduced (blue lines) CD8+ T cells from B6 (top row) and BALB/c
(bottom row) mice. Figures within each plot indicate mean fluorescence intensity (MFI) for each marker. Data are representative of two independent
experiments. All statistically significant comparisons are depicted with the relevant p value; all other comparisons are not significantly different.
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F5-TCR, indicative of greater turnover of the former population.
Although CD8 expression was equivalent at transfer, we consis-
tently observed reduced expression in T cells expressing the
MDM2-TCR compared with control T cells at days 15 (data not
shown) and 22 (Fig. 3D), a finding consistent with tuning of
coreceptor expression in the presence of Ag (29, 30).
Although these data were indicative that theMDM2-TCR but not
the F5-TCR was triggered by Ag in vivo, analysis of peripheral
tissues demonstrated absence of immunopathology (Supplemental
Fig. 4) and, importantly, as a global measure of health, there were
no differences in recipient weights between the groups. This
suggested that MDM2-TCR–transduced CD8+ T cells did not
effect tissue damage upon Ag encounter in vivo. Indeed, when
we tested the capacity for each TCR-transduced population to
induce in vivo cytotoxicity against B cells pulsed with relevant
peptide, we noted nearly complete lysis of pNP366-loaded cells
in recipients of F5-TCR T cells, but only partial lysis of the
pMDM2-loaded targets in recipients of MDM2-TCR T cells
(Fig. 4A, 4B). To confirm that the dysfunction of MDM2-
TCR–transduced CD8+ T cells was a consequence of self-
antigen exposure, we compared in vivo cytotoxicity of MDM2-
TCR–transduced B6 or BALB/c T cells following their transfer to
B6 or BALB/c hosts, respectively. As shown in Fig. 4C, specific
cytotoxicity was significantly greater in Ag-free BALB/c mice
compared with Ag-expressing B6 hosts. Therefore, upon transfer
to Ag-expressing hosts, CD8+ T cells expressing the MDM2-TCR
FIGURE 3. MDM2-TCR–transduced T cells tune CD8 expression upon transfer to Ag-expressing recipients. Immunomagnetically selected CD8+ T cells
of B6 origin were transduced with the MDM2 or F5-TCR. Identical numbers of B6 MDM2-TCR–transduced or B6 F5-TCR–transduced CD8+ T cells were
adoptively transferred to sublethally irradiated B6 mice. (A) A tail bleed was carried out on days 15 and 22 following transfer. The left plot shows the
forward scatter (FSC) and side scatter (SSC) profile used to gate on lymphocytes. The right plots show representative CD45.1 and CD8 staining profiles
used to identify the adoptively transferred lymphocytes in recipients of MDM2-TCR–transduced CD8+ T cells (upper plot) or of F5-TCR–transduced CD8+
T cells (lower plot). The graph on the right shows the frequency of adoptively transferred (CD45.1+CD8+) lymphocytes as a percentage of circulating
lymphocytes at days 15 and 22 after transfer. (B) Absolute numbers of MDM2- and F5-TCR–transduced CD8 T cells populations in lymph nodes, spleen,
and bone marrow 4 wk after transfer. Data are pooled from four independent experiments. (C) Proliferation of MDM2-transduced (red) and F5-TCR–
transduced (blue) CD8 T cell populations within the spleen was determined by BrdU incorporation after oral administration of BrdU between days 24 and
29 after transfer. Representative flow cytometric histograms of BrdU staining (left, numbers represent mean fluorescence intensity [MFI] of BrdU within
adoptive population) and summary data (right) are shown. (D) Surface expression of CD8b on circulating MDM2-TCR–transduced (CD45.1+c-myc+) and
F5-TCR–transduced cells (CD45.1+ Vb11+) at day 22 following transfer. Representative flow cytometric histograms of CD8b versus CD45.1 staining (left)
and summary data of MFI of CD8b on MDM2-TCR–transduced (▴) and F5-TCR–transduced (;) cells are shown (right). All statistically significant
comparisons are depicted with the relevant p value; all other comparisons are not significantly different.
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are not deleted but rather tune down CD8 coreceptor expression
and lose cytotoxic function.
We next explored whether in vitro Ag exposure was required for
the observed reduction of effector function in vivo. Lethally ir-
radiated CB6F1 mice were reconstituted with a mixture of Rag2/2
B6 bone marrow cells and T cell–depleted BALB/c bone marrow
cells (see Materials and Methods). The T cells of the reconstituted
F1 mice were of BALB/c origin, tolerant to the H2
b haplotype,
and unable to present the H2-Kb–restricted pMDM100. These
T cells were isolated, transduced with the MDM2-TCR in vitro,
and adoptively transferred into chimeric recipients presenting
the TCR-recognized Ag in hematopoietic or nonhematopoietic
tissues. As expected, the transferred T cells showed strong cyto-
toxicity in BALB/c→BALB/c recipients where there was an
absence of TCR-recognized Ag (Fig. 4D). Cytotoxic function was
retained in mice presenting pMDM100 in the hematopoietic
compartment (Fig. 4D, B6→BALB/c recipient chimeras), but was
substantially reduced when Ag presentation occurred in non-
hematopoietic tissues (BALB/c→B6 recipient chimeras). These
experiments indicate nonhematopoietic Ag induced T cell dys-
function, and that this dysfunction did not depend on Ag pre-
sentation during T cell transduction in vitro.
Provision of CD4+ T cell help enhances cytotoxic function of
MDM2-TCR–transduced CD8+ T cells
To determine whether MDM2-TCR–transduced CD8+ T cell cy-
totoxicity could be restored through provision of help, we trans-
ferred MDM2-TCR–transduced CD8+ T cells to conditioned B6
recipients together with OVA-specific Rag2/2 OT-II–TCR trans-
genic CD4+ T cells (Fig. 5A). Following T cell transfer, mice were
immunized with B6 DCs loaded with pOVA323 peptides or ir-
relevant peptides. Recipient mice receiving DCs pulsed with
pOVA323 peptide demonstrated a significant increase in in vivo
cytotoxicity compared with mice receiving DCs loaded with
control peptide (Fig. 5B). The observed increase in cytotoxicity
was associated with an increase in MDM2-TCR–transduced CD8+
T cell numbers in the spleen, with a similar trend in the bone
marrow and lymph nodes (Fig. 5C), and an increase in CD8
coreceptor expression within the MDM2-TCR+ T cell population
(Fig. 5D). To further demonstrate that cognate recognition by
CD4+ T cells was required for the provision of help in vivo, we
adoptively transferred polyclonal mock-transduced CD4+ T cells.
As shown in Fig. 5E, polyclonal CD4+ T cells did not improve
cytotoxicity of MDM2-TCR–transduced CD8+ T cells.
CD4+ T cells transduced with the MDM2-TCR partially
overcome tolerance of CD8+ T cells transduced with same
TCR
We have shown previously that CD4+ T cells bearing an MHC-I–
restricted TCR (F5) can enhance the antitumor activity of CD8+
T cells bearing the same TCR using a model Ag that is tumor-
specific and not expressed in normal tissues (17). We were
therefore interested whether CD4+ T cells engineered to express
the MDM2-TCR could rescue the function of CD8+ T cells ren-
FIGURE 4. MDM2-TCR–transduced T cells demonstrate reduced cytotoxicity after transfer to Ag-expressing recipients. The Ag-specific function of
adoptively transferred MDM2- and F5-TCR–transduced CD8+ T cells in B6 hosts was assessed on days 26–29 after transfer by means of an in vivo
cytotoxicity assay. This compared lysis of pMDM100-loaded (CFSElow) against pNP366-loaded (CFSEhigh) B6 B cell targets in the spleen 16 h after the B
cells were injected i.v. as a 1:1 mix. (A) Representative histograms showing each target population within spleens of recipients of mock, MDM2-TCR– and
F5-TCR–transduced CD8+ T cells. A change in the ratio of these populations relative to one another indicates specific lysis of one target population. This is
calculated as percentage specific lysis, as described in Materials and Methods. (B) Summary specific lysis of B cell targets in recipients of MDM2-TCR–
and F5-TCR–transduced CD8+ T cells. Data are from five independent experiments. (C) B6 or BALB/c MDM2-TCR–transduced CD8+ T cells (0.75–1 3
106) were transferred to sublethally irradiated B6 or BALB/c hosts, respectively, and on days 26–29 in vivo cytotoxicity was determined as before, although
using CB6F1 target cells pulsed with pMDM100 or pNP366 peptide. Summary data from three independent experiments are shown. (D) BALB/c-derived
(Thy1.1) T cells that were tolerant to Kb (seeMaterials and Methods) were transduced with the MDM2-TCR. Of these cells, 0.2–0.53 106 were transferred
into sublethally irradiated recipient chimeras in which cognate Ag was either restricted to the hematopoietic compartment (B6→BALB/c), completely
absent (BALB/c→BALB/c), or restricted to the nonhematopoietic compartment (BALB/c→B6). Fifteen days after transfer, an in vivo cytotoxicity assay
was performed using CB6F1 B cells pulsed with pMDM100 or pNP366 peptide and summary data are shown (pooled from three independent experiments).
All statistically significant comparisons are depicted with the relevant p value; all other comparisons are not significantly different.
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dered hyporesponsive by a naturally expressed TAA in normal
tissues. Using the experimental design in Fig. 6A, we transferred
MDM2-TCR–transduced CD8+ T cells or MDM2-TCR–trans-
duced CD4+ T cells or both populations together to conditioned
B6 mice and performed in vivo cytotoxicity assays as before. As
shown in Fig. 6B, we observed significantly greater cytotoxicity
against pMDM100-pulsed targets where both transduced CD4+
and CD8+ T cells were transferred. As in the OVA help model, we
consistently observed an increase in CD8 coreceptor expression
within the transduced CD8+ T cell population upon cotransfer of
CD4+ and CD8+ T cells compared with mice that received CD8+
T cells in isolation (Fig. 6C).
From these data, however, it was not possible to distinguish
whether MDM2-TCR–transduced CD4+ T cells were providing
help or contributed directly to the killing of pMDM100-loaded
targets. To investigate this, we transferred MDM2-TCR–trans-
duced CD8+ T cells and an equal number of either MDM2-TCR–
transduced or mock-transduced CD4+ T cells into Ag-expressing
hosts. Additionally, we also administered a CD8-depleting mono-
clonal or isotype control Ab throughout the experiment. In mice
receiving CD8-depleting Ab, any residual cytotoxic activity could
be attributed to the transferred CD4+ T cell population alone or
other non-CD8 populations in the host. In the presence of CD8
depletion, in vivo cytotoxicity of pMDM100-pulsed target cells was
not different in recipients of MDM2-TCR–transduced CD4+
T cells or mock-transduced CD4+ T cells (Fig. 6D), indicating that
the MDM2-TCR–expressing CD4+ T cells did not display specific
killing above the background seen with polyclonal CD4+ T cells.
Whereas the Ag-specific cytotoxicity of MDM2-TCR–transduced
CD8+ T cells was improved in the presence of MDM2-TCR–
transduced CD4+ T cells, there was no evidence of immunopa-
thology in mice receiving both of these populations. Specifically,
there was weight loss in recipients of MDM2-TCR–transduced
CD4+ and CD8+ T cell populations compared with mice receiving
F5-TCR–transduced CD4+ and CD8+ T cells, and, additionally, the
histologies of liver, lung, skin, and colon from these recipient mice
were normal (Supplemental Fig. 3).
Cointroduction of the CD8 coreceptor blocks the helper
functions of MDM2-TCR–expressing CD4+ T cells
Unlike MDM2-TCR–transduced CD8+ T cells, CD4+ T cells
expressing the same TCR did not demonstrate increased activa-
tion as determined by increased cell size (Fig. 7B). If lack of the
CD8 coreceptor in MDM2-TCR–transduced CD4+ T cells per-
mitted them to avoid tolerance and confer help, then introduction
of CD8a and CD8b coreceptor chains may impede their ability to
help (Fig. 7A). Consistent with recognition of MDM2, the co-
transduction of CD8ab and MDM-TCR into B6 CD4+ T cells
resulted in increased cell size, although less than the size seen
in B6 CD8+ T cells transduced with the MDM2-TCR only
(Fig. 7B). Similarly, upregulation of the CD69 activation marker
was less pronounced in CD4+ T cells expressing TCR plus CD8
compared with CD8+ T cells expressing the TCR only (Fig. 7C).
Unlike CD8+ T cells, the TCR+ CD8–expressing CD4+ T cells
did not show upregulation of activation markers CD44 and PD-1.
This in vitro analysis showed that the self-antigen–triggered
FIGURE 5. Provision of heterologous help
improves the functions of MDM2-TCR–trans-
duced CD8+ T cells in vivo. (A) MDM2-TCR–
transduced CD8+ T cells (0.5 3 106) and 0.5 3
106 OT-II CD4+ T cells were cotransferred to
sublethally irradiated B6 mice. Forty hours later,
recipient mice received 0.5 3 106 LPS-matured
DCs loaded with pOVA323 or control peptide. (B)
On day 25 following transfer, Ag-specific
responses of MDM2-TCR–transduced CD8+
T cells were assessed by an in vivo cytotoxicity
assay against peptide-loaded B cell targets de-
termined as previously described. (C) Absolute
number of adoptively transferred MDM2-TCR–
transduced CD8+ T cells in secondary lymphoid
organs at day 25. (D) Summary data of surface
expression of CD8b on circulating MDM2-TCR–
transduced (CD45.1+c-myc+) T cells within the
spleen were determined on day 25. Data in (A)–
(D) are pooled from two independent experi-
ments. (E) MDM2-TCR–transduced CD8+ T cells
and CD4+ T cells (which had been activated with
CD3/CD28 beads for 24 h) were transferred to
sublethally irradiated B6 mice and in vivo cyto-
toxicity against peptide-loaded B cell targets was
determined as before at 28 d following transfer
(data pooled from two independent experiments).
All statistically significant comparisons are depicted
with the relevant p value; all other comparisons
are not significantly different.
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T cell activation was more effective in CD8+ T cells compared
with CD4+ T cells expressing the same TCR plus the CD8 co-
receptor.
Despite apparently reduced activation in vitro, the in vivo
analysis revealed that TCR plus CD8 transfer abolished the abil-
ity of the CD4+ T cells to provide helper function. Whereas CD4+
T cells expressing TCR only improved the cytotoxicity of CD8+
T cells, this was not the case with transfer of CD4+ T cells
expressing TCR plus CD8 (Fig. 7D). Further analysis showed
that help provided by TCR-transduced CD4+ T cells increased the
number of MDM2-TCR–transduced CD8+ T cells (Fig. 7E); this
increase seemed primarily due to an accumulation of activated
CD8+ T cells that lost expression of CD62L (Fig. 7F). The in-
crease in CD8+ T cell numbers and loss of CD62L expression
were not seen when CD4+ T cells were transduced with the
MDM2-TCR plus CD8. Taken together, the data show that the
dysfunction of MDM2-TCR–transduced CD8+ T cells in Ag-
expressing hosts can be partially reversed by cotransfer of CD4+
T cells engineered to express an identical TCR, where the absence
of the CD8 coreceptor enables preservation of Th function.
Discussion
To our knowledge, we have shown for the first time that an
identical MHC-I–restricted TCR can confer tolerance or helper
function upon transfer to CD8+ and CD4+ T cells, respectively.
Absence of the CD8 coreceptor was critical in enabling CD4+
T cells to maintain helper functions and avoid dysfunction upon
interaction with MHC-I–presented peptide ligands.
Our data indicate the in vivo induction of unresponsiveness
mediated by a TCR specific for a tumor-associated self-antigen was
dependent on the presence of CD8. CD8 improves TCR signaling
by increasing the stability of the TCR binding to MHC/peptide and
enhancing the availability of p56Lck at the immunological synapse
(31). Thus, the data presented in the present study indicate that
improved T cell stimulation resulted in tolerance induction,
whereas weak T cell stimulation maintained immune function
despite chronic Ag exposure. This is supported by in vitro data
showing that both B6 origin CD8+ T cells expressing the MDM2-
TCR and CD4+ T cells expressing TCR plus CD8 were activated
by self-antigen, whereas this was not the case when CD4+ T cells
expressed TCR alone. The lack of robust in vitro activation of
TCR-transduced CD4+ T cells may be due to insufficient sensi-
tivity or relevance of the assays used, whereas chronic in vivo
exposure to MDM2 Ag may sustain weak TCR signals that are
sufficient for helper functions. Other weak near threshold TCR
signals in CD4+ T cells leading to in vivo functional outputs in
CD4+ T cells include clonal competition in the periphery in re-
sponse to lymphopenia (32). The notion that reducing TCR signal
strength may improve in vivo function is also supported by a study
showing that artificial lowering of p56Lck availability in CD4+
T cells improved their capacity to generate helper cytokines in
response to chronic stimulation by a TAA (33).
Upon in vivo transfer to Ag-expressing hosts, MDM2-TCR–
transduced CD8+ T cells were not deleted. Instead, they demon-
strated increased turnover and CD8 downtuning consistent with
ongoing antigenic stimulation (34, 35). Tuning of CD8 expression
FIGURE 6. Transfer of MDM2-TCR–transduced CD4+ T cells improves the functions of MDM2-TCR–transduced CD8+ T cells in vivo. (A) MDM2-
TCR–transduced CD8+ T cells (0.5–1 3 106) with or without the same number of MDM2-TCR–transduced CD4+ T cells were transferred to sublethally
irradiated B6 mice. A further group received 0.5–1 3 106 MDM2-TCR–transduced CD4+ T cells without CD8+ T cells. (B) Ag-specific responses of the
adoptive populations were determined using an in vivo cytotoxicity assay against peptide-loaded B cell targets at 25–29 d following transfer. Data are
pooled from five independent experiments. (C) Summary data of surface expression of CD8b on splenic MDM2-TCR–transduced CD8+ T cells at days 25–
29 after transfer without or with MDM2-TCR–transduced CD4+ T cells. Data are pooled from five independent experiments. (D) Conditioned B6 recipients
received 0.5 3 106 MDM2-TCR–transduced CD8+ T cells and either 0.5 3 106 MDM2-TCR–transduced CD4+ or 0.5 3 106 CD3/CD28 bead–activated
polyclonal CD4+ T cells. The indicated cohorts were also treated with weekly i.p. injections of a CD8-depleting or isotype Ab. CD8 depletion was .95%.
An in vivo cytotoxicity assay was carried out on day 25, and the specific lysis of pMDM2-loaded targets was determined as before. Data are pooled from
two independent experiments. All statistically significant comparisons are depicted with the relevant p value; all other comparisons are not significantly
different.
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is also observed in other models of peripheral tolerance, where
TCR stimulation interrupts the normal homeostatic regulation that
maintains CD8 transcription via IL-7R– and STAT5-mediated
signaling (35). CD8 tuning may explain the lack of autoimmune
pathology in this model despite transfer of high-avidity T cells
reactive to a widely expressed self-antigen.
Although removal from Ag and exposure to common g cyto-
kines may reset CD8 coreceptor expression and increase func-
tional TCR avidity (35), these strategies are unlikely to be
applicable in a clinical context. We therefore evaluated cotransfer
of conventional MHC-II–restricted CD4+ T cells or MHC-I–re-
stricted T cells expressing the MDM2-TCR. In both cases, help
provided by CD4+ T cells increased CD8 coreceptor expression
in MDM2-specific CD8+ T cells, which was associated with in-
creased in vivo cytotoxicity against peptide-pulsed target cells, in
the absence of detectable reactivity against normal tissues with
low expression of MDM2.
Tolerance induction in MDM2-TCR–expressing CD8+ T cells
was driven by interactions with the nonhematopoietic compart-
ment. Indeed, when MDM2 Ag presentation was limited to he-
matopoietic cells, their immune function was preserved. Although
there are many possible mechanisms contributing to the tolero-
genic function of nonhematopoietic tissues, we would like to
speculate on a role of costimulation. For example, costimulatory
ligands such as CD80, CD86 and CD154 are more abundant on
hematopoietic host cells, whereas nonhematopoietic tissues may
provide cognate TCR stimulation without providing costimula-
tion. The presence of signal 1 without signal 2, such as in the latter
scenario, has previously been linked to tolerance induction (36).
In CD4+ T cells expressing only the MDM2-TCR, a weak TCR
FIGURE 7. MDM2-TCR–transduced CD4+ T cells coexpressing CD8ab coreceptor cannot provide help to tolerant MDM2-TCR–transduced CD8+
T cells. (A) CD4 T cells were cotransduced with MDM2-TCR and CD8ab. Representative CD4 and CD8b staining of gated c-myc+ (MDM2-TCR+) cells is
shown. Percentages refer to the populations within the depicted gates. (B) Representative histograms of forward scatter (FSC) at day 3 following trans-
duction of MDM2-TCR–transduced CD4+ T cells (blue line) compared with MDM2-TCR–transduced CD8+ T cells (red line) or MDM2-TCR–transduced
CD4+ T cells cotransduced with CD8ab (black line). (C) Representative staining profiles of CD44, CD62L, CD69, and PD-1 expression in gated c-myc+
(MDM2-TCR+) CD4+ T cells (blue line), CD8+ T cells (red line), or CD4+ T cells cotransduced with CD8ab (black line). (D) MDM2-TCR–transduced
CD8+ T cells (1 3 106) were transferred to sublethally irradiated B6 hosts with or without the same number of CD4+ T cells cotransduced with MDM2-
TCR and CD8ab or transduced with the MDM2-TCR alone. At day 25 after transfer an in vivo cytotoxicity assay was carried out against peptide-loaded B
cell targets (data pooled from two independent experiments). (E) Absolute numbers and (F) CD62L staining profile of splenic MDM2-TCR–expressing
CD8+ T cells in each of the indicated experimental groups. All statistically significant comparisons are depicted with the relevant p value; all other
comparisons are not significantly different.
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signal 1 combined with a strong signal 2 delivered by professional
APCs appeared sufficient to maintain helper function without
induction of tolerance. Furthermore, enhancing TCR signaling
through forced expression of CD8 appeared sufficient to lead to
tolerance induction in such CD4+ T cells.
MDM2 is a suitable target TAA, as it is involved in oncogenesis
and is overexpressed in a high proportion of cancers (6–8).
However, MDM2 is also present in normal tissues and its ex-
pression sharply increases following T cell activation (37), when it
acts via p73 to inhibit transcription of Bim and prevent activation-
induced cell death (28). This could increase endogenous presen-
tation of Kb/pMDM100 by T cells, leading to recognition through
the transduced TCR and T cell killing. Indeed, this was observed
following transduction of T cells with other allorestricted TCRs.
Thus, HLA-A2+ CD8 T cells transduced with HLA-A2–restricted
TCRs specific for two TAAs, survivin and HMMR, demonstrated
fratricide in vitro as a result of increased protein expression fol-
lowing T cell activation (38). In our experiments, we were unable
to demonstrate fratricide of MDM2-TCR–transduced T cells in
vitro or in vivo.
In conclusion, our data indicate a potential means for over-
coming tolerance of CD8+ T cells to a TAA. Upon transfer of
CD8+ T cells to Ag-expressing hosts, induction of dysfunction by
TAA exposure on normal tissues may be overcome by transfer of
CD4+ T cells bearing the same TCR.
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Supplementary Figure 1. Recognition of endogenous peptide by MDM2-TCR expressing T 
cells. (A) MDM2-TCR and LoMDM2-TCR transduced T cells were tested for their ability to kill H2b 
MDM2-expressing tumor cell lines MBL-2 (left) and C205 (right). MBL-2 and C205 tumor cells 
were used because they were also killed by the original CTL from which the MDM2-TCR was 
isolated (see ref. 11 for analysis of the original CTL). RMA-S cells coated with the irrelevant 
peptide (pSV9) were included as a control for non-specific background killing. (B) Flow cytometric 
analysis of PD-1 expression was carried out 7 days post transduction of splenocytes from 
C57BL/6 (B6) or BALB/c mice. Top- Representative histograms show the PD-1 staining profile of 
B6 splenocytes after gating on CD8+/c-myc+ (MDM2-TCR+) T cells (red) or CD8+/c-myc- (MDM2-
TCR-) T cells (blue). Bottom- PD-1 staining profile of gated CD8+/c-myc+ B6 T cells (red) 
compared to gated CD8+/c-myc+ BALB/c T cells (black). (C) Flow cytometric analysis of 
expression of PD-1, LAG-3, 2B4, NKG2A was carried out 7 days post transduction of B6 
splenocytes. Cells were transduced with MDM2-TCR (red line), F5-TCR (black line) and 
compared to naïve un-transduced T cells (green line). Representative histograms are shown of 
the expression of the indicated molecules on gated live CD8+/c-myc+ (MDM2-TCR transduced) or 
CD8+/Vβ11+ (F5 TCR transduced) T cells. Numbers in the top right of each histogram are the 
median fluorescence intensity (MFI) of that marker on the gated T cell population. Results are 
representative of at least 2 independent experiments 
	  	  
	  
 
Supplementary Figure 2. Enhanced apoptosis in MDM2 TCR transduced CD8+ T cells of B6 mice. 
B6 and BALB/c splenocytes were transduced with MDM2 and LoMDM2-TCRs. On day 4 post transduction 
gated CD8+ T cells were analyzed for annexin V and propidium iodide (PI) staining. Plots show the 
proportion of T cells in early (upper left) and late (upper right) apoptosis, gated in the left hand plots on c-
myc+ (TCR+) T cells, c-myc- (TCR-) cells in the right-hand plots. Data are representative of 2 independent 
experiments.   
  
 
 
 
Supplementary Figure 3. MDM2-TCR-transduced CD8+ T cells from BALB/c but not B6 mice 
show antigen-specific IFNγ  production after stimulation with pMDM100-loaded targets. B6 or 
BALB/c (H2-Kb negative) splenocytes were transduced with MDM2-TCR. On day 5 post transduction, 
they were stimulated with RMA-S targets loaded with relevant pMDM100 peptide (Rel peptide) or 
control peptide (Irrel peptide) overnight and the IFNγ response determined by intracellular cytokine 
staining. (A) Summary results from 5 experiments of the IFNγ response from B6-derived MDM2-TCR 
transduced CD8+ T cells. (B) Representative histograms of intracellular IFNγ staining of MDM2-TCR 
transduced B6 and BALB/c CD8+ T cells are shown. These results are representative of 2 independent 
experiments. 
  
 
 
 
 
 
Supplementary Figure 4. Recipients of MDM2-TCR transduced T cells do not show histological 
evidence of immunopathology MDM2-TCR transduced CD8+ T cells with or without the same 
number of MDM2-TCR transduced CD4+ T cells were transferred to sub-lethally irradiated B6 mice. At 
25-29 days following transfer, the mice were sacrificed and samples of skin, liver, lung and colon were 
taken for histopathological assessment, which was carried out in a single blind fashion. There was no 
detectable tissue pathology in mice treated with MDM2-TCR CD8+ T cells, or MDM2-TCR CD8+ and 
CD4+ T cells. (A) Representative histology sections of skin (upper left), colon (upper right), liver (lower 
left), lung (lower right) of recipients of MDM2-TCR transduced CD8+ T cells. (B) Representative 
histology sections of skin (upper left), colon (upper right), liver (lower left), and lung (lower right) of 
recipients of MDM2-TCR transduced CD4+ and CD8+ T cells. 
